Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

199
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
199
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moving Too Fast? A Meta-Analysis Calls for Caution on TNF Inhibitors as First-Line Therapy for Autoimmune Hepatitis.

Journal of hepatology·2026
Same author

Risk factors for poor response to autoimmune hepatitis: A systematic review and meta-analysis.

Clinics and research in hepatology and gastroenterology·2026
Same author

Two Atypical Cases of Adams-Oliver Syndrome With DOCK6 Genetic Variants.

American journal of medical genetics. Part A·2026
Same author

Novel LAMA1 Mutations in a Pedigree With Poretti-Boltshauser Syndrome: Implications for Hypomyelination.

Molecular genetics & genomic medicine·2026
Same author

METTL4 enhances GLI1 translation through m<sup>6</sup>Am modification to promote tumor progression as a therapeutic target for hepatocellular carcinoma.

Journal of advanced research·2026
Same author

Extracellular vesicles in autoimmune diseases: Mechanistic underpinnings and precision medicine applications.

Autoimmunity reviews·2025

Related Experiment Video

Updated: Jan 10, 2026

Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases
06:21

Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases

Published on: October 6, 2023

2.5K

Metabolomics in autoimmune hepatitis: progress and perspectives.

Xiaotong Huang1, Wenhui Mo2, Xiaoning Wang3,4

  • 1Basic Medical College, Naval Medical University, Shanghai, China.

Frontiers in Medicine
|November 20, 2025
PubMed
Summary

Metabolomics advances offer new hope for autoimmune hepatitis (AIH) diagnosis and treatment. This approach analyzes metabolites to understand disease mechanisms and identify biomarkers for personalized care.

Keywords:
artificial intelligenceautoimmune hepatitisdiagnosismetabolomicsmicrobiome

More Related Videos

Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy
07:54

Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy

Published on: December 15, 2011

13.4K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.8K

Related Experiment Videos

Last Updated: Jan 10, 2026

Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases
06:21

Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases

Published on: October 6, 2023

2.5K
Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy
07:54

Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy

Published on: December 15, 2011

13.4K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.8K

Area of Science:

  • Biochemistry
  • Immunology
  • Hepatology

Background:

  • Autoimmune hepatitis (AIH) is a chronic liver disease with complex, immune-mediated injury.
  • Understanding AIH pathogenesis requires integrating genetic, immunological, and environmental factors.
  • Metabolomics provides a systems-level view of small molecule metabolites in disease.

Purpose of the Study:

  • To review recent advancements in applying metabolomics to autoimmune hepatitis (AIH).
  • To highlight metabolomics' potential in AIH diagnosis, prognosis, and therapy evaluation.
  • To discuss challenges and future directions for metabolomics in AIH research.

Main Methods:

  • Utilizing metabolomics, a systems-wide approach analyzing small molecule metabolites.
  • Employing techniques like liquid chromatography-mass spectrometry (LC-MS) for metabolite profiling.
  • Applying bioinformatics for biomarker discovery and pathway analysis.

Main Results:

  • Identified alterations in amino acid, lipid, carbohydrate, and bile acid metabolism in AIH.
  • Observed changes in gut microbiome composition and specific metabolite profiles distinguishing AIH.
  • Demonstrated metabolomics' utility in identifying potential AIH biomarkers.

Conclusions:

  • Metabolomics shows significant promise for early AIH diagnosis and prognosis.
  • Further research can refine personalized treatment strategies for AIH patients.
  • Integrating multi-omics and AI approaches will enhance understanding and clinical outcomes in AIH.